Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1Other 1Lymphoid 1Head & Neck 1

Conditions

Mucositis 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Exercise 28Metformin 24Surveys and Questionnaires 19Radiotherapy 14Methods 14Early Intervention, Educational 13Counseling 13Educational Status 12naloxegol 10Standard of Care 10Tirzepatide 9Nutrition Assessment 9Diet Therapy 9Cisplatin 9Resistance Training 8Psychiatric Rehabilitation 8Diet 8Therapeutics 7Interviews as Topic 7alvimopan 6Liraglutide 6Fibroblast Growth Factor 7 6Caloric Restriction 6semaglutide 5Radiation 5Low-Level Light Therapy 5Injections 5Exenatide 5Diet, Mediterranean 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pain Management × Other × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡